|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Ceragenix Pharmaceuticals Inc., of Denver, began enrolling patients in a trial to assess EpiCeram compared to Cutivate, a mid-strength steroid, in patients with moderate to severe atopic dermatitis. The company expects to have results in the fourth quarter. The study will consist of 90 children between the ages of 6 months and 18 years, with half receiving treatment with EpiCeram and the other half receiving the steroid for a four-week period. Ceragenix received 510(k) clearance in April from the FDA to market EpiCeram to improve dry skin conditions and to relieve symptoms associated with various dermatoses.
o Nastech Pharmaceutical Co. Inc., of Bothell, Wash., ...